The IVECT Method
Intezyne's IVECT Method is a unique and remarkably safe platform that has the potential to raise the bar in terms of what patients and oncologists can expect from chemotherapy. The key to this breakthrough technology is the Companys multi-disciplinary approach, integrating polymer physics and materials science with organic chemistry, polymer chemistry, biochemistry, and biology. Intezyne can improve patient outcomes significantly by amplifying the efficacy and safety profiles of best-in-class cancer drugs, whose potency often is handicapped by nonspecific delivery outside of the tumor site, requiring higher dosing and resulting in severe toxicities. The IVECT Method has proven to be extraordinarily versatile, in terms of the diversity of materials that can be encapsulated securely, and its unique modular design confers unmatched adaptability at a minimal cost. Beyond chemotherapy, the Company has proven the IVECT Method can deliver many classes of small molecules, in addition to nucleic acids, oligopeptides, and diagnostic imaging agents.

The IVECT Methods distinct hallmark consists of four proprietary characteristics:

1. Stability. Intezyne dramatically reduces drug toxicity by securely encapsulating the active therapeutic agent in the proprietary IVECT micelle, a polymeric nanoparticle that minimizes drug exposure to healthy tissues. Also, the IVECT Micelle shields its contents from the bodys natural defenses, allowing higher concentrations of the active drug to reach the tumor without being excreted or degraded. Additionally, Intezyne's proprietary cross-linking technology can provide enhanced protection and increased anti-tumor activity by creating a triggered release mechanism, which actively dispenses the drug payload only at the tumor site.
   
   
2. Tunability. The IVECT copolymer is equipped with proprietary means of attaching cell targeting groups, which anchor the IVECT Micelle to the tumor, both quickly and easily. Because of this breakthrough in modular drug design, Intezyne is able to focus the drugs anti-tumor activity to diverse tumor types without having to synthesize distinct tumor-optimized therapies from scratch.
   
   
3. Solubility. Many promising therapeutics never reach their full potential because they are poorly soluble in the bloodstream, and some require the creation of a prodrug compound to be administered effectively. With the IVECT Method, Intezyne is able to bypass these issues through secure encapsulation of the active compound. Insoluble drugs previously deemed unfeasible can be sequestered safely and effectively from the bloodstream until they reach the tumor.
   
   
4. Versatility. The IVECT Method has proven the ability to accommodate an expansive range of materials, not limited to best-in-class therapeutics, with only two distinct copolymers. This versatility not only gives Intezyne a strong position in oncology, but, through strategic licensure, Intezyne can profit from the universality of the IVECT Method in an ever-expanding variety of therapeutic and diagnostic settings.

Intezyne has demonstrated cost-efficient commercial scale manufacturing of the IVECT copolymer, while maintaining the highest quality standards.

Product Development
Intezyne currently has four cancer chemotherapeutics in its pipeline: two lead programs in final preparation for IND submission and two others in earlier stages of preclinical development.

The Companys lead program, IT-141, has shown significant activity against a diverse number of cancer cell lines. Advanced preclinical studies showed IT-141 is extremely well tolerated, and significantly outperforms Pfizer's Camptosar (irinotecan), which shares the same active component. Intezyne plans to file an IND for IT-141 for the treatment of metastatic colorectal cancer.

IT-143, Intezynes drug encapsulating daunorubicin, is being evaluated for treatment of  lung cancer, osteosarcoma, and ovarian cancer. In addition to being well tolerated, IT-143 demonstrated superior pharmacokinetics versus free daunorubicin and its current formulations. Advanced preclinical studies currently are underway and will conclude this year.

Intezyne is gaining new ground in the area of tumor-specific gene therapy. The Companys IT-121 program is in early preclinical testing and thus far has demonstrated target gene expression far superior to that of commercially available gene transfection systems. Unlike other gene therapy programs, IT-121 minimizes accumulation in the liver.